Today, Church & Dwight, Co., Inc., the makers of First Response™ pregnancy and ovulation tests, announced the launch of First Response™ Pregnancy PRO Digital Pregnancy Test & App Access – their latest innovation and the first and only Bluetooth Smart-enabled pregnancy test on the market. First Response™ Pregnancy PRO connects to a woman’s smart device through a mobile application. Once synced, the app provides her with pregnancy-related content only available with Pregnancy PRO, and delivers a personalized user experience throughout her entire pregnancy journey.
“We are thrilled to be unveiling the next generation of in-home pregnancy testing on a stage like CES, where so many technological advancements have made their debut,” said Stacey Feldman, Vice President of Marketing, Church & Dwight. “With Pregnancy PRO, we’ve leveraged unique consumer insights to develop a product that not only revolutionizes the pregnancy test category, but more importantly, provides women with the information they need during their journey.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7725251-first-response-pregnancy-pro/
Square Enix, Inc., the publisher of SQUARE ENIX® interactive entertainment products in the Americas today announced FINAL FANTASY® XIII-2 for the Xbox 360® video game and entertainment system from Microsoft and PlayStation®3 computer entertainment system is now available at retailers.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54433-square-enix-inc-announces-final-fantasy-xiii-2-now-available-at-retailers
Square Enix, Inc., the publisher of Square Enix® interactive entertainment products in North America, announced today that the eagerly anticipated 13th entry in the series, FINAL FANTASY® XIII, is now available at retail outlets across the nation. Developed for both the PlayStation®3 computer entertainment system and the Xbox 360® video game and entertainment system from Microsoft, FINAL FANTASY XIII marks the dawning of a new era for the celebrated franchise.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/squareenix/42400/
Do you feel financially prepared for the future? If you’re not completely confident in your response, you’re not alone. In fact, a recent survey conducted by Research Now Group, Inc. and commissioned by Fifth Third Private Bank (NASDAQ: FITB) found that nearly half of those surveyed have serious concerns that they may outlive their money in retirement.
The Bank launched the survey to understand families’ financial planning pain points and gain insight into how the process could be simplified through its new platform, Life360.
“The study confirmed the anxiety that clients have shared with our advisors is reflective of similar concerns nationally,” said Phil McHugh, executive vice president and head of Wealth and Asset Management at Fifth Third. “Much of that anxiety stems from a lack of clearly articulated financial goals and alignment around achieving them. Our Life360 platform works to help simplify, focus and holistically address these critical aspects of the financial planning process.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7723854-fifth-third-bank-life360
The world of food keeps getting bigger.
Embodying a culinary destination for food aficionados paired with the convenience of a full-service market, Giant Eagle, Inc. today unveiled its fifth Market District location in five years – and its first in Pittsburgh’s North Hills suburbs.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54165-giant-eagle-new-market-district-location-pittsburgh-north-hills
Feed The Children and World Neighbors announced today that as of March 1, 2013 World Neighbors will become a subsidiary of Feed The Children, Inc. The two Oklahoma City based nonprofits will join forces as strategic partners to better serve those in need worldwide.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60079-feed-the-children-and-world-neighbors-unite
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
The Jones Group Inc. (NYSE: JNY) today announced the launch of the QMack brand, a new collection focused on the millennial customer exclusively available at Macy’s and macys.com. The QMack collection is a wardrobing system that focuses on key items and classic shapes with a girly twist meant to be “mixed and macked” to create the ultimate, effortless uniform.
Inspired by all-American style, QMack also incorporates a global flair by way of Parisian and London influences to create classics with a twist in a multitude of colors and materials, including: go-to blazers, gathered minis, prep school skater skirts, roll sleeve blouses as well as easy dresses and cardigans. The name QMack was inspired by a composite of muses and the classic pieces they wore and then re-imagined to create a modern version for today. Prices range from $29 to $299.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62723-the-jones-group-inc-q-mack-new-uniform-for-millennials-macys
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Ethicon, Inc., a worldwide leader in surgical care, has announced its entrance into the barbed suture market with the launch of its new portfolio of STRATAFIX™ Knotless Tissue Control Devices, representing the next evolution in wound closure technology. With significantly more points of fixation than traditional sutures, STRATAFIX™ Devices give surgeons more consistent control over every pass (through the tissue), and combine the strength and security of interrupted closure with the efficiency of continuous closure.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58405-ethicon-launches-stratafix-knotless-tissue-control-devices